Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trials Completed
343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 343 Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer